Journal article
Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
Abstract
PURPOSE: High-strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing.
METHODS: We conducted a longitudinal study among patients receiving publicly funded, high-strength opioids from August 2016 to July 2017. The primary outcome measure was weekly median daily opioid dose (in milligrams of …
Authors
Martins D; Khuu W; Tadrous M; Juurlink DN; Mamdani MM; Paterson JM; Gomes T; Network OBOTODPR
Journal
Pharmacoepidemiology and Drug Safety, Vol. 28, No. 5, pp. 726–733
Publisher
Wiley
Publication Date
5 2019
DOI
10.1002/pds.4764
ISSN
1053-8569